Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2019 · 10-K
Revenue$53.67M$53.67M−10.9% vs Q4 2018 Net Income-$34.40M-$34.40MN/M vs Q4 2018 EPS Diluted-$0.24-$0.24N/M vs Q4 2018 Gross Profit$6,006,000+18.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$26,625,000N/M Free Cash Flowderived-$27,266,000N/M Margins · derivedGross margin11.2%+2.8 pt vs Q4 2018
Operating margin-59.7%−59.6 pt vs Q4 2018
Net margin-64.1%−60.6 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 24, 2020 · 55 d after period end